Lawrence C. Fritz joined Anadys as President and Chief Executive
Officer and a member of the Board of Directors on November 20, 2006.
Previously, he founded and developed several successful biotechnology
companies. He founded Conforma Therapeutics and served as its President
and CEO from inception in 1999 through its acquisition by Biogen Idec
in 2006. Conforma pioneered a new approach to cancer therapy,
developing drugs that induce tumor cells...
more
Lawrence C. Fritz joined Anadys as President and Chief Executive
Officer and a member of the Board of Directors on November 20, 2006.
Previously, he founded and developed several successful biotechnology
companies. He founded Conforma Therapeutics and served as its President
and CEO from inception in 1999 through its acquisition by Biogen Idec
in 2006. Conforma pioneered a new approach to cancer therapy,
developing drugs that induce tumor cells to degrade their deregulated
signaling proteins. Dr. Fritz is also a founder and Director of
Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out
from Conforma in conjunction with Biogen Idec's acquisition. Prior to
Conforma, Dr. Fritz co-founded both Athena Neurosciences, now
wholly-owned by Elan Corporation, and Idun Pharmaceuticals,
subsequently acquired by Pfizer. As Vice President of Research at
Athena, his work led to the clinical development of products for
multiple sclerosis, Alzheimer's disease, and neuromuscular disorders.
While Executive Vice President, Research at Idun, he led R&D teams
that pioneered pharmaceutical applications in the field of programmed
cell death, or apoptosis. These efforts led to new approaches to the
treatment of hepatitis C, inflammation, and cancer. Dr. Fritz holds an
A.B. Degree in Biochemical Sciences from Harvard, a M.Sc. Degree in
Physiology from University College London, and a Ph.D. in Biophysics
from The Rockefeller University.
less
